5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Lamberti, Monica ^a   Porto, Stefania ^b   Marra, Monica ^b   Zappavigna, Silvia ^b   Grimaldi, Anna ^b   Feola, Daniela ^a   Pesce, Delia ^b   Naviglio, Silvio ^b   Spina, Annamaria ^b   Sannolo, Nicola ^a   Caraglia, Michele ^b  

^a Occupational Medicine   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

5 Fluorouracil; Apoptosis; Cardiotoxicity; Doxorubicin; Health workers; ROS

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; DOXORUBICIN; FLUOROURACIL; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CARDIOTOXICITY; CELL DAMAGE; CELL GROWTH; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; GROWTH INHIBITION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DOXORUBICIN; FLOW CYTOMETRY; FLUOROURACIL; HT29 CELLS; HUMANS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS;

EID: 84865042947     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-60     Document Type: Article

References (42)

1. The genotoxic risk in health care workers occupationally exposed to cytotoxic drugs-a comprehensive evaluation by the SCE assay. Kopjar N, Kasuba V, Rozgaj R, et al. J Environ Sci Health, Part A: Tox Hazard Subst Environ Eng 2009 44 5 462 479 10.1080/10934520902719845
2. Lack of genotoxicity in medical oncology nurses handling antineoplastic drugs: effect of work environment and protective equipment. Gulten T, Evke E, Ercan I, et al. Work 2011 39 4 485 489 21811037
3. Cytogenetic analysis of peripheral blood lymphocytes of hospital staff occupationally exposed to low doses of ionizing radiation. Eken A, Aydin A, Erdem O, et al. Toxicol Ind Healt 2010 26 5 273 280 10.1177/0748233710365693
4. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Fucic A, Jazbec A, Mijic A, et al. Mutat Res 1998 416 59 66 10.1016/S1383-5718(98)00084-9 9725992 (Pubitemid 28398846)
5. Analysis of cyclophosphamide in the urine of antineoplastic drugs handlers. Favier B, Gilles L, Desage M, et al. Bull Cancer 2003 90 10 905 909 14706919 (Pubitemid 37487108)
6. Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Undeger U, Basaran N, Kars A, et al. Mutat Res 1999 439 277 285 10.1016/S1383-5718(99)00002-9 10023083 (Pubitemid 29094820)
7. Evaluation of occupational genotoxic risk in a Brazilian hospital. Maluf SW, Erdtmann B, Genet Mol Biol 2000 23 485 488 10.1590/S1415-47572000000200040 (Pubitemid 30623727)
8. Follow-up study of genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Maluf SW, Erdtmann B, Mutat Res 2000 471 21 27 10.1016/S1383-5718(00)00107-8 11080657
9. Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical handling antineoplastic drugs. Kopjar N, Garaj-Vrhovac V, Mutagenesis 2001 16 71 78 10.1093/mutage/16.1.71 11139601 (Pubitemid 32050829)
10. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Turci R, Sottani C, Ronchi A, et al. Toxicol Lett 2002 134 57 64 10.1016/S0378-4274(02)00163-7 12191861 (Pubitemid 35007286)
11. The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. Faust F, Kassie F, Kanasmuller S, et al. Mutat Res 2004 566 209 229 10.1016/j.mrrev.2003.09.007 15082238 (Pubitemid 38472028)
12. Investigating genetic damage in workers occupationally exposed to methotrexate using three genetic end-points. Deng H, Zhang M, He J, et al. Mutagenesis 2005 20 351 313 10.1093/mutage/gei048 16037120 (Pubitemid 41219864)
13. Assessment of chromosomal aberrations, micronuclei and proliferation rate index in peripheral lymphocytes from Tunisian nurses handling cytotoxic drugs. Bouraoui S, Brahem A, Tabka F, et al. Environ Toxicol Pharmacol 2011 31 1 250 257 10.1016/j.etap.2010.11.004 21787692
14. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Rekhadevi PV, Sailaja N, Chandrasekhar M, et al. Mutagenesis 2007 6 395 401 (Pubitemid 350098495)
15. Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. Rombaldi F, Cassini C, Salvador M, et al. Mutagenesis 2009 24 143 148 19011124
16. International Agency for Research on Cancer, Monographs on the evaluation of the carcinogenic risk of chemicals to humans: pharmaceutical drugs IARC, Lyon, France 2001
17. Lipp. Cardiotoxicity of cytotoxic drugs, Anticancer drug toxicity: prevention, management and clinical pharmacokinetics Marcel Dekker, New York 1999 471 488
18. Chemotherapy-induced cardiotoxicity. Shaikh AY, Shih JA, Curr Heart Fail Rep 2012 9 2 117 127 10.1007/s11897-012-0083-y 22382639
19. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Albini A, Pennesi G, Donatelli F, et al. J Natl Cancer Inst 2010 102 14 25 10.1093/jnci/djp440 20007921
20. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Yeh ET, Tong AT, Lenihan DJ, et al. Circulation 2004 109 3122 3131 10.1161/01.CIR.0000133187.74800.B9 15226229
21. Sodium nitroprusside induces cell death and cytoskeleton degradation in adult rat cardiomyocytes in vitro: implications for anthracycline-induced cardiotoxicity. Chiusa M, Timolati F, Perriard JC, et al. Eur J Histochem 2012 56 2 15 22688296
22. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and preventionreview of the literature. Wojtacki J, Lewicka-Nowack E, Lesniewski-Kmak K, Med Sci Monit 2000 6 411 420 11208348 (Pubitemid 30313187)
23. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Sawyer DB, Zuppinger C, Miller TA, et al. Circulation 2002 105 1551 1554 10.1161/01.CIR.0000013839.41224.1C 11927521 (Pubitemid 34297631)
24. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? Minotti G, Cairo G, Monti E, FASEB J 1999 13 2 199 212 9973309 (Pubitemid 29072398)
25. Pathogenesis of cardiotoxicity induced by anthracyclines. Elliott P, Semin Oncol 2006 33 2 S7 17178277
26. 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Jensen SA, Sørensen JB, Cancer Chemother Pharmacol 2012 69 1 57 64 10.1007/s00280-011-1669-x 21603868
27. Fluorouracil cardiotoxicity. Anand AJ, Ann Pharmacother 1994 28 374 378 8193429 (Pubitemid 24105515)
28. Change in TNF- receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. Chiosi E, Spina A, Sorrentino A, et al. J Interferon Cytokine Res 2007 27 589 597 10.1089/jir.2006.0161 17651020 (Pubitemid 47122718)
29. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Tsibiribi P, Descotes J, Lombard-Bohas C, Barel, et al. Bull Cancer 2006 93 27 E30 16567310
30. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Lieutaud T, Brain E, Golgran-Toledano D, et al. Eur J Canc 1996 32a 368 369
31. Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. alk AN, eliker E, Velibey Y, et al. Am J Emerg Med 2012 30 1 257.e1 e3 10.1016/j.ajem.2010.10.025
32. Acute Reversible Heart Failure Caused by Coronary Vasoconstriction due to Continuous 5-Fluorouracil Combination Chemotherapy. Dechant C, Baur M, Böck R, et al. Case Rep Oncol 2012 5 2 296 301 10.1159/000339573 22740819
33. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. Castiglia L, Miraglia N, Pieri M, et al. J Occup Health 2008 50 1 48 56 10.1539/joh.50.48 18285644 (Pubitemid 351680007)
34. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Büchel B, Rhyn P, Schürch S, et al. Biomed Chromatogr 2012 10.1002/bmc.2741
35. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Caraglia M, Marra M, Budillon A, et al. Cancer Biol Ther 2005 4 10 1159 1167 10.4161/cbt.4.10.2206 16294035 (Pubitemid 41598574)
36. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Correale P, Marra M, Remondo C, et al. Eur J Cancer 2010 46 9 1703 1711 10.1016/j.ejca.2010. 03.005 20399639
37. Cardiotoxicity of 5-fluorouracil. Alter P, Herzum M, Soufi M, et al. Cardiovasc Hematol Agents Med Chem 2006 4 1 1 5 16529545 (Pubitemid 43796695)
38. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Oztop I, Gencer M, Okan T, et al. Jpn J Clin Oncol 2004 34 5 262 268 10.1093/jjco/hyh047 15231861 (Pubitemid 43102887)
39. A case of acute myocardial infarction during 5-fluorouracil infusion. Canale ML, Camerini A, Stroppa S, et al. J Cardiovasc Med 2006 7 11 835 837 10.2459/01.JCM.0000250874.09273.9b (Pubitemid 44632200)
40. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Asensio-Lápez MC, Lax A, Pascual-Figal DA, et al. Free Radic Biol Med 2011 51 10 1861 1871 10.1016/j.freeradbiomed.2011.08.015 21907790
41. Colorectal carcinoma cells-regulation of survival and growth by SGK1. Lang F, Perrotti N, Stournaras C, Int J Biochem Cell Biol 2010 42 10 1571 1575 10.1016/j.biocel.2010.05.016 20541034
42. Apoptosis in cancer: from pathogenesis to treatment. Wong RSY, J Exp Clin Cancer Res 2011 30 87 10.1186/1756-9966-30-87 21943236